We are live on ! Find out more
VC

Vivo Capital Portfolio holdings

AUM $1.2B
1-Year Est. Return 911.44%
This Fund
S&P 500
This Quarter Est. Return
-5.19%
1 Year Est. Return
+911.44%
3 Year Est. Return
+7,373.93%
5 Year Est. Return
+10,475.15%
10 Year Est. Return
+136,503.27%
AUM
$1.1B
AUM Growth
-$269M
Cap. Flow
-$108M
Cap. Flow %
-9.78%
Top 10 Hldgs %
61.03%
Holding
57
New
53
Increased
–
Reduced
–
Closed
4

Top Buys

Rank Stock Value
1
ASND icon
Ascendis Pharma A/S
ASND
+$260M
2
NFH
New Frontier Health Corporation Ordinary Shares
NFH
+$130M
3
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$68.1M
4
KDMN
Kadmon Holdings, Inc.
KDMN
+$54M
5
ARQT icon
Arcutis Biotherapeutics
ARQT
+$45.3M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 87.06%
2 Financials 10.69%
3 Materials 1.51%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ASND icon
1
Ascendis Pharma A/S
ASND
$16.3B
$226M 20.43%
+2,003,147
New +$260M
NFH
2
DELISTED
New Frontier Health Corporation Ordinary Shares
NFH
$118M 10.69%
+14,300,000
New +$130M
KDMN
3
DELISTED
Kadmon Holdings, Inc.
KDMN
$52.5M 4.76%
+12,539,515
New +$54M
ARQT icon
4
Arcutis Biotherapeutics
ARQT
$3.53B
$50.3M 4.55%
+1,686,527
New +$45.3M
CRNX icon
5
Crinetics Pharmaceuticals
CRNX
$8.88B
$48.8M 4.42%
+3,320,801
New +$68.1M
ZYME icon
6
Zymeworks
ZYME
$1.65B
$39.1M 3.54%
+1,101,236
New +$45.1M
SVA
7
DELISTED
Sinovac Biotech, Ltd
SVA
$38.2M 3.46%
+5,900,000
New +$38.2M
FTSV
8
DELISTED
Forty Seven, Inc. Common Stock
FTSV
$37.8M 3.42%
+395,691
New +$23.9M
PASG icon
9
Passage Bio
PASG
$14.3M
$35.1M 3.18%
+111,479
New +$34.9M
AVDL
10
DELISTED
Avadel Pharmaceuticals
AVDL
$28.4M 2.57%
+3,575,424
New +$27.5M
ARWR icon
11
Arrowhead Research
ARWR
$11.8B
$22.1M 2%
+768,674
New +$31M
ZGNX
12
DELISTED
Zogenix, Inc.
ZGNX
$22M 1.99%
+888,724
New +$32.4M
VSTM icon
13
Verastem
VSTM
$541M
$21.5M 1.95%
+678,295
New +$17M
RNAC icon
14
Cartesian Therapeutics
RNAC
$224M
$18.9M 1.71%
+261,550
New +$25.3M
SRRA
15
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$18.8M 1.71%
+1,917,074
New +$25.1M
AKRO
16
DELISTED
Akero Therapeutics
AKRO
$17.1M 1.55%
+808,247
New +$17.3M
CDXS icon
17
Codexis
CDXS
$136M
$16.7M 1.51%
+1,493,903
New +$20.9M
AMRS
18
DELISTED
Amyris Inc.
AMRS
$16.6M 1.51%
+6,492,247
New +$18.9M
KRTX
19
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$16.1M 1.46%
+223,692
New +$19.1M
LITS
20
Lite Strategy Inc
LITS
$33.4M
$15.8M 1.43%
+489,221
New +$19.6M
QTTB icon
21
Q32 Bio
QTTB
$459M
$15.7M 1.42%
+56,031
New +$17.2M
MYOK
22
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$15.6M 1.42%
+333,621
New +$21.4M
KDNY
23
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$14M 1.27%
+1,023,712
New +$12.1M
ORTX
24
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
$12.3M 1.11%
+162,723
New +$18.7M
EIGR
25
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$12.2M 1.1%
+59,709
New +$19M
1
2 3

Similar funds

SGDR
SPX Gestao de Recursos Rio De Janeiro, Brazil $1.2B AUM 59.05% 1-Year Est. Return
WC
Whitney & Co Rochester, New York $1.2B AUM 24.16% 1-Year Est. Return
FCCPG
FountainVest China Capital Partners GP3 Grand Cayman, Cayman Islands $1.2B AUM 6.95% 1-Year Est. Return
GP
Guardian Partners Toronto, Canada $1.2B AUM 35.94% 1-Year Est. Return
RCYC
Richard C. Young & Co Newport, Rhode Island $1.21B AUM 38.41% 1-Year Est. Return
AIM
Anchor Investment Management Columbia, South Carolina $1.2B AUM 17.33% 1-Year Est. Return
CA
Callahan Advisors Houston, Texas $1.2B AUM 22.34% 1-Year Est. Return
SC
Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return

Vivo Capital's Q1 2020 Portfolio in Review

As of Q1 2020, Vivo Capital held 57 positions worth $1.1B, down 20% from $1.37B the previous quarter. Its ten largest holdings account for 61% of the portfolio.

Vivo Capital withdrew a net $108M in Q1 2020, closing 4 positions.

By sector, the portfolio is most concentrated in Healthcare at 87% of assets, followed by Financials and Materials.

Against the trend, Vivo Capital opened a new position in Ascendis Pharma A/S worth $226M.

  • Vivo Capital's largest Q1 2020 buy was Ascendis Pharma A/S: 2,003,147 shares worth $226M.
  • Vivo Capital's ten largest holdings make up 61% of its $1.1B portfolio in Q1 2020.
  • Vivo Capital opened 53 new positions and closed 4 in Q1 2020.
  • Vivo Capital's portfolio value fell 20% quarter-over-quarter to $1.1B.

Based on Vivo Capital's 13F filing for Q1 2020, filed 15 May 2020.